Thiazolidinedione use and bone loss in older diabetic adults. - Wikidata - awgldk - TriplyDB

Thiazolidinedione use and bone loss in older diabetic adults.

Thiazolidinedione use and bone loss in older diabetic adults.

http://www.wikidata.org/entity/Q35023205

about

Rosiglitazone for type 2 diabetes mellitus The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis Nuclear receptors in bone physiology and diseases Treating the elderly diabetic patient: special considerations Management of endocrine disease: Secondary osteoporosis: pathophysiology and management GQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR ) Ligand, Promotes Insulin Sensitization without Weight Gain Recognizing and treating secondary osteoporosis Nocturnin suppresses igf1 expression in bone by targeting the 3' untranslated region of igf1 mRNA Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting.Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats Thiazolidinediones are partial agonists for the glucocorticoid receptor.Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.Skeletal effects of the saturated 3-thia Fatty Acid tetradecylthioacetic Acid in rats.A novel PPARγ2 modulator sLZIP controls the balance between adipogenesis and osteogenesis during mesenchymal stem cell differentiation Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Emerging therapeutic opportunities for skeletal restoration.Bone mineral density and factors influencing it in Asian Indian population with type 2 diabetes mellitus.Retinaldehyde dehydrogenase 1 deficiency inhibits PPARγ-mediated bone loss and marrow adiposity.Predictors of the rate of BMD loss in older men: findings from the CHAMP study.Impaired musculoskeletal response to age and exercise in PPARβ(-/-) diabetic mice Risk management in the treatment of type 2 diabetes with pioglitazone Effects of thiazolidinediones on bone loss and fracture.Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.The role of incretins in glucose homeostasis and diabetes treatment.PPARγ: a circadian transcription factor in adipogenesis and osteogenesis.Lean mass predicts hip geometry in men and women with non-insulin-requiring type 2 diabetes mellitus Correlates of trabecular and cortical volumetric bone mineral density of the radius and tibia in older men: the Osteoporotic Fractures in Men Study.Resolving the Two "Bony" Faces of PPAR-gamma.Cellular and molecular effects of thiazolidinediones on bone cells: a review.Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells.Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis Diabetes, TZDs, and Bone: A Review of the Clinical Evidence.Rosiglitazone and pioglitazone alter aromatase kinetic properties in human granulosa cells Novel insights into the relationship between diabetes and osteoporosis

P2860

Q24243875-49745D9A-9DB2-4B1A-8982-88EB999FC25F Q24601222-FE149891-A5A9-4252-A52E-35EEF7E41A30 Q24655666-5201A171-B11E-407A-B88A-786A34952F84 Q26853017-7442270B-3E0A-4FD7-89FC-A23D983E4B90 Q26995176-542BF548-53CB-43E6-A59E-FA9EF3D8C328 Q26998249-B7B1D2D9-F767-439C-8224-3850DE9C0AA0 Q27679090-9CB79948-AE6F-4E69-B228-984233400CF4 Q28270738-4C5C59B0-B799-402F-84BB-E8639F74CACB Q28589935-18C99088-A2DD-4389-905F-FB175BFB6D86 Q33424057-791B291A-A62B-4636-BB31-111B0D3D7123 Q33607697-BBC4E774-7AA7-438E-B9EC-EFCDF9FAEB87 Q33706603-024D7534-6719-45D5-934D-E0C2E1F2C732 Q33736122-87BEF769-5A70-4D10-85EA-BB39FBAE8E95 Q33797616-925D0CE5-E2E1-440A-9AB9-F058BF99B90F Q33874663-9EE31BE0-D318-4AA1-8492-DF56CB3D0B70 Q33912894-AC0544AA-3E0F-4F9E-A2CA-8B75C5942918 Q33948063-49DDC492-EA4E-45A0-A9BF-C3D3FA47F5EF Q34090872-502B6D8D-3ADD-4447-8A51-F6FAD629D529 Q34108417-DD8B8656-7ECD-4D55-8FA5-CFC07E4EA277 Q34153540-5A6E19BA-11BA-4ADF-AA8A-04C6E12A66B2 Q34161200-4D077325-AF2F-414D-AA7F-9FB9AF1D4FD3 Q34161867-BABC3E2A-E5A5-40E8-BD25-AC2B34BD0957 Q34319701-CCA9D08A-2031-488E-83CC-3224F0901C62 Q34402668-F49CA51D-F758-4823-B9EB-15291655B7FD Q34501378-69F88B6A-BC49-4A76-94A6-38FE84EF19C5 Q34551710-C62FD3E8-DE99-4B84-95C1-6A6776C7FFC4 Q34620706-6DBBA0C5-ABCF-4FE0-9ECA-65C49526A3C7 Q34701705-0AE55552-6053-493F-A46F-0D8C79F737A1 Q34888374-1F8BB652-F1FE-4758-B140-CE1F41842C35 Q34901533-B9C05EE5-7417-4D06-8739-DCB6BC6C07E7 Q35093192-3F9B7A9E-2308-4C69-B139-32D99DFBFC02 Q35147358-38CE7918-9331-43DE-9D61-7F0BEBBFC15D Q35156177-6B1A7F1A-FFE6-44A3-ADFE-7064090F45FB Q35191573-47955829-C52C-42BC-9223-BC411573B9AC Q35346767-7BC3B679-D572-4916-A2F0-DEE6A92FC055 Q35528700-6CB74602-8736-40F6-9AD8-8DBB39EE8656 Q35561066-348BBD86-0E10-45D9-8109-EFAE5F954589 Q35606042-46EDC3B9-EB74-4401-AC2D-11737EDE34F0 Q35636330-256B1572-0F09-4D3D-BDE7-A667BE936961 Q35674683-156B80F0-1AD4-4D26-A552-C3CE4BF3274D

P2860

Thiazolidinedione use and bone loss in older diabetic adults.

http://www.wikidata.org/entity/Q35023205

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Thiazolidinedione use and bone loss in older diabetic adults.

@ast

Thiazolidinedione use and bone loss in older diabetic adults.

@en

type

label

Thiazolidinedione use and bone loss in older diabetic adults.

@ast

Thiazolidinedione use and bone loss in older diabetic adults.

@en

prefLabel

Thiazolidinedione use and bone loss in older diabetic adults.

@ast

Thiazolidinedione use and bone loss in older diabetic adults.

@en

P1433

Q35023205-797104A7-0E01-489F-BC25-F163D8FDC52F

P1476

Q35023205-3C3E61B7-6382-4AAA-9840-0A1CA6220602

P2093

Q35023205-09055133-A451-43F5-94CE-7A9F6DBB075D

Q35023205-1EA7B9CB-50B7-428B-8847-E28FB99852E6

Q35023205-205F9410-F31A-4397-B749-A24B668616C8

Q35023205-2250EF0D-0540-4A27-BC51-9FECE72F9ABE

Q35023205-6E239FC2-2806-4FF3-ACB9-FB6F163A1411

Q35023205-7D072574-3795-47F8-A569-33BDE761114E

Q35023205-86872F62-7743-4DC9-A787-C8C95F47BADE

Q35023205-97E3176A-2D4E-4977-8823-D6C91421D5FE

Q35023205-E7585BFE-883D-4134-A32A-C0B68CBE0D66

Q35023205-EB72FDDB-C24B-49F6-A603-C927E8F432A7

P2860

Q35023205-02835C02-DDA9-469E-A658-37235959C025

Q35023205-09B89650-6539-445B-A3D1-224ADF202FCA

Q35023205-173A4A3C-35B1-4951-909A-AE592B329110

Q35023205-20BEF34E-EC75-44AC-A46F-C98934E46585

Q35023205-432A4AED-DAC3-4CCF-B914-DCAB4486EA8C

Q35023205-47A9670C-EC90-40B7-9CC9-E0FD316B67C6

Q35023205-50D65F9F-4E60-443C-9371-EE90A86E7EFC

Q35023205-551FB4D0-7D6F-483F-A34E-CAE41D38E27A

Q35023205-5B4AA907-D611-4FB9-99DA-EDE6D30F1A7B

Q35023205-61391A4B-0398-412B-9DCB-FDE6B613733C

P304

Q35023205-DCD3850A-0DE6-4F29-BA4B-7BAC1F0A5125

P31

Q35023205-0FE0B07F-597F-49EE-96F3-E9240FA4BD8F

P356

Q35023205-49678CCD-F514-4895-9CAA-8DB9CC42C0D8

P407

Q35023205-0ACBE7DA-7DB8-4EF8-A197-818A023462A3

P433

Q35023205-FB6E7695-DA85-4EED-B0A4-6028D8B12FB8

P478

Q35023205-8245A3A8-7AB9-4A98-A700-BBE0E4E33E3A

P50

Q35023205-B143638C-E582-4FCE-8125-5FB316E8F46C

Q35023205-E59FD73E-E2DE-423D-B6B2-01E7B6B2972A

Q35023205-F35306D3-E91C-4016-BD8A-92FDCD9E8067

P577

Q35023205-5D0FA967-9701-471D-8C52-76A9ABBDE748

P5875

Q35023205-0261F3A4-FDDB-4800-ADBC-F320052AF6E8

P698

Q35023205-4BF98C1D-8AC1-462D-B437-228655AD4B03

P932

Q35023205-F7141EDF-6DE0-4BFB-A963-D3210081BEA2

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Thiazolidinedione use and bone loss in older diabetic adults.

@en

P2093

Ann V Schwartz

http://www.w3.org/2001/XMLSchema#string

Beata Lecka-Czernik

http://www.w3.org/2001/XMLSchema#string

Brock A Beamer

http://www.w3.org/2001/XMLSchema#string

Deborah E Sellmeyer

http://www.w3.org/2001/XMLSchema#string

Helaine E Resnick

http://www.w3.org/2001/XMLSchema#string

Kenneth R Feingold

http://www.w3.org/2001/XMLSchema#string

Laura Carbone

http://www.w3.org/2001/XMLSchema#string

Lisa Palermo

http://www.w3.org/2001/XMLSchema#string

Nancy E Lane

http://www.w3.org/2001/XMLSchema#string

Seok Won Park

http://www.w3.org/2001/XMLSchema#string

P2860

Ex vivo bone mineral density of the wrist: influence of medullar fat.

Glitazones and the management of insulin resistance: what they do and how might they be used.

Thiazolidinediones.

Bone is a target for the antidiabetic compound rosiglitazone.

Drug data coding and analysis in epidemiologic studies.

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.

Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.

Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice.

P304

3349-3354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2005-2226

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P50

Eric Vittinghoff

Elsa S. Strotmeyer

Tamara B Harris

P577

2006-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7171052

http://www.w3.org/2001/XMLSchema#string

P698

16608888

http://www.w3.org/2001/XMLSchema#string

P932

1563497

http://www.w3.org/2001/XMLSchema#string